NewsAI-assisted

Cognizant Achieves Global Elite Partner Status with ServiceNow

Cognizant earns Global Elite status with ServiceNow, highlighting its AI-driven solutions and client success.

Mrudula Kulkarni
By Mrudula Kulkarni
Managing Editor - Pharma Now
Jan 31, 2025Updated Jun 26, 2025 · 2 min read
Cognizant Achieves Global Elite Partner Status with ServiceNow
AI-assisted reporting
Reviewed by Mrudula Kulkarni, Managing Editor - Pharma Now

Cognizant has reached a significant milestone in its partnership with ServiceNow, earning the prestigious Global Elite status—the highest level of recognition in the ServiceNow Partner Program. With only six partners worldwide achieving this distinction, Cognizant’s elevation underscores its expertise in AI-powered solutions, workflow transformation, and customer success. The achievement is a testament to Cognizant’s investment in innovation, its deep industry knowledge, and its ability to drive business value across the ServiceNow ecosystem.

The Cognizant ServiceNow Business Group has played a crucial role in this success, leveraging AI, automation, and strategic partnerships to develop industry-specific solutions. "We are honored to be recognized as a Global Elite partner by ServiceNow and remain committed to delivering transformative solutions for our clients," said Sriramkumar Kumaresan, Cognizant’s global head of Cloud, Infrastructure, and Security. ServiceNow leaders also praised Cognizant’s ability to enhance workflows, streamline data integration, and create seamless enterprise experiences. As Cognizant continues expanding its capabilities, the company is well-positioned to drive the next wave of digital transformation in collaboration with ServiceNow.

TopicsNews
Mrudula Kulkarni
Written by
Mrudula Kulkarni
Managing Editor - Pharma Now

My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.



Discussion

Loading discussion…

More from Pharma News

All stories →